6Quinn J P, Studemeister A E, Di Vencenzo C A. Resistance to imipenem in pseudomonas aeruginosa:clinical experience and bio chemical mechanisms[J]. Rev Infect Dis, 1998,10:892-898.
2Ohgaki N. Bacterial biofilm in chronic airway infection[J].Kansen Shogaku-Zasshi, 1994, 68(1):138-151.
3Ichimiya T, Yamasaki T, Nasu M. In-vitro effects of antimicrobial agents on Pseudomonas aeruginosa biofilms formation[J]. J Antimicrob Chemother, 1994, 34(3):331-341.
4Nagino K, Kobayashi H. Influence of macrolides on mucoid alginate biosynthetic enzyme from Pseudomonas aeruginos[J]. Clin Microbiol Infect, 1997, 3(4): 432-439.
5Bustamante CI, Wharton RC, Wade JC. In vitro activity of ciprofloxacin in combination with ceftazidime, aztreonam, and azlocillin against multiresistant isolate of Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother,1990,34(9):1814-1815.
6Dudley M N, Blaser J, Gilber D, et al. Combination therapy with ciprofloxacin plus azlocillin against Pseudomonas aeruginosa : effect of simultaneous versus staggered administration in an in vitro model of infection[J]. J Infect Dis, 1991,164(3):499-506.
7Klepser ME, Patel KB, Nicolau DP, et al. Comparison of bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother, 19
6Kamboj M, Sepkowitz K A. Nosocomial infections in patients with cancer[J]. Lancet Oneol, 2009, 10(6) :589-597.
7Vento S, Cainelli F, Temesgen Z. Lung infections after cancer ehemotherapy[J]. Lancet Oncol, 2008, 9(10):982-992.
8Alp E, Gtiven M, Yildiz O, et al. Incidence, risk factors and mortality of nosoeomial pneumonia in intensive care units: a pro spective study [J]. Ann Clin Mierobiol Antimicrob, 2004, 3(17):1 7.
9Miano T A, Reichert M G, Houle T T, et al. Nosocomial pneu- monia risk and stress ulcer prophylaxis: a comparison of panto prazole vs ranitidine in cardiothoracic surgery patients [J]. Chest, 2009,136(2) :440-447.
10Yamada Y, Sekine Y, Suzuki H, et al. Trends of bacterial colo nisation and the risk of postoperative pneumonia in lung cancer patients with chronic obstructive pulmonary disease[J]. Eur J Cardiothorac Surg, 2010, 37(4) :752-757.
